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ABSTRACT 
Objective: Ramelteon, is a sleep agent that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding 
to GABAA
Methods: Colon-targeted tablets were prepared in two steps. Initially, core tablets were prepared and then the tablets were coated by using 
different pH dependent polymers. Ethylcellulose, Eudragit RLPO and L100 were used as enteric coating polymers. The precompression blend of all 
formulations was subjected to various flow property tests and all the formulations were passed the tests. The tablets were coated by using polymers 
and the coated tablets were subjected to physical characterization, drug content, in vitro drug release and kinetics of drug release.  
 receptors. In the present research work, the formulation of ramelteon targeted to colon by using various polymers developed. 
Results: Among all the formulations, F4 formulation was found to be optimized as it was retarded the drug release up to 18 h and showed 
maximum of 99.25% drug release. It followed the first-order kinetics mechanism. All the formulations having Korsmeyer-Peppas ‘n’ values are in 
the range of 0.540 to 0.818. Hence, it was concluded that the prepared formulations followed non-Fickian diffusion. 
Conclusion: An effective and stable remelteon colon targeted formulation developed for treating insomnia. 
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INTRODUCTION 
Now a days a novel oral colon-specific drug delivery system (CDDS) 
has been developed as one of the site-specific drug delivery systems. 
This delivery system, by means of the combination of one or more 
controlled release mechanisms, hardly releases drug in the upper part 
of the gastrointestinal (GI) tract, but rapidly releases drug in the colon 
following oral administration. First, as for treating localized colonic 
diseases, i.e. ulcerative colitis, Crohn’s disease and constipation etc., 
the optimal drug delivery system, such as CDDS, should selectively 
deliver drug to the colon, but not to the upper GI tract [1, 2]. Second, 
the colon is referred to as the optimal absorption site for protein and 
polypeptide after oral administration, because of the existence of 
relatively low proteolytic enzyme activities and quite long transit time 
in the colon. Finally, CDDS would be advantageous when a delay in 
absorption is desirable from a therapeutically point of view, as for the 
treatment of diseases that have peak symptoms in the early morning 
and that exhibit circadian rhythms, such as nocturnal asthma, angina 
and rheumatoid arthritis. There were currently a few strategies to 
achieve colonic specificity, such as use of pH sensitive polymers and 
pressure-controlled CDDS. The aim of this study was to explore the 
feasibility of the colonic microorganism to develop CDDS by using 
paracetamol as a model drug. Polysaccharides, the polymer of 
monosaccharides retains their integrity because they are resistant to 
the digestive action of gastrointestinal enzymes [3]. The matrices of 
polysaccharides are assumed to remain intact in the physiological 
environment of the stomach and small intestine, but once they reach in 
the colon, they are acted upon by the bacterial polysaccharides and 
results in the degradation of the matrices. A large number of 
polysaccharides such as amylose, guar gum, pectin, chitosan, inulin, 
cyclodextrins, chondroitin sulphate, dextrans, dextrin and locust bean 
gum have been investigated for their use in colon targeted drug 
delivery systems [4, 5]. The most important fact in the development of 
polysaccharide derivatives for colon targeted drug delivery is the 
selection of a suitable biodegradable polysaccharide. As these 
polysaccharides are usually soluble in water, they must be made 
water-insoluble by cross linking or hydrophobic derivatization, very 
important is an optimal proportional of the hydrophobic and 
hydrophilic parts, respectively and the number of free hydroxyl 
groups in the polymeric molecule. The present study includes the 
preparation of ramelteon colon targeted tablets by using compression 
coating technology.  
MATERIALS AND METHODS 
Materials 
Ramelteon was obtained as gift sample from Dr. Reddys 
Laboratories, Hyderabad, Andhrapradesh.  
Formulation of remelteon tablets 
Ramelteon colon targeted tablets were prepared by using compression 
coating technology. Initially, internal core tablet containing drug and 
super disintegrate was formulated. For the prepared core tablet 
compression coating is done by using various compositions of polymers. 
Ethyl cellulose, Polymethacrylate polymers such as Eudragit RLPO and 
Eudragit S100 are used as polymers for compression coating [6, 7]. 
Formulation of core tablet 
The core tablets are formulated by using 8 mg of the drug molecule, 
Cross carmellose sodium as super disintegrate, Micro crystalline 
cellulose as diluent, talc and magnesium stearate as Glidant and 
Lubricant, respectively. The composition of core tablet was given in 
below table 1. 
 
Table 1: Composition of core tablet 
Ingredient name Quantity (mg) 
Ramelteon 8 
Cross carmellose sodium 32 
Talc 3 
Magnesium stearate 3 
MCC pH102 34 
Total weight 80 
 Total weight of the core tablet was fixed as 80 mg. The tablets are prepared by using 6 mm flat punch. Then the prepared core tablets are subjected 
to compression coating by using various compositions of polymers. 
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Formulation of compression coated tablets 
The prepared core tablets were subjected to compression coating by 
using various compositions of polymers such as Ethylcellulose, 
Eudragit L 100 and Eudragit S 100 as coating materials [8, 9]. The 
composition of coating layer is given in below table 2. 
 
Table 2: Composition of the coating layer 
Ingredient name F1 F2 F3 F4 F5 F6 F7 F8 F9 
Ethyl cellulose (mg) 40 80 ---- ---- ---- ---- 40 ---- 40 
Eudragit RLPO (mg) ---- ---- 40 80 ---- ---- 40 40 ---- 
Eudragit L 100 (mg) ---- ---- ---- ---- 40 80 ---- 40 40 
Magnesium stearate (mg) 3 3 3 3 3 3 3 3 3 
Talc (mg) 3 3 3 3 3 3 3 3 3 
MCC pH 102 (mg) 174 134 174 134 174 134 174 134 174 
Total weight  220 220 220 220 220 220 220 220 220 
 
Compression coating layer was divided into two equal portions i.e., 
110 mg of each quantity. Half of the quantity of powder blend was 
placed in the die cavity, core tablet was placed exactly in the middle 
of die cavity and then remaining quantity of powder blend was 
placed over the core tablet so that the powder blend should cover all 
the sides and top side of core tablet uniformly. Then the tablets are 
compressed by using 9 mm flat-surfaced punch using 8 station tablet 
punching machine with the hardness of 4-4.5 kg/cm2
Physical characterization of fabricated tablets 
. Then the 
prepared compression coated tablets are evaluated for various post-
compression parameters as per standard specifications. 
Hardness 
The hardness of the tablet was determined by using a Monsanto 
hardness tester and expressed in kg/cm2 
Uniformity of thickness 
[10, 11]. 
The thickness of the three tablets was measured using Vernier 
calipers. The extent to which the thickness of each tablet deviates 
from±5% of the standard value was determined. 
Friability 
Percentage friability is calculated by given formulae that tells how 




W1=Weight of tablets before test, W2
Weight variation 
=Weight of tablets after the 
test. 
Individual weights of 20 tablets were taken and the average weight 
was calculated by using the following formula and variation should 
not be more than 5 %. 
Weight variation= Weight of tablet−Average weight
Average weight of tablets
x100 
Determination of drug content 
Both compression-coated tablets of were tested for their drug 
content. Ten tablets were finely powdered quantities of the powder 
equivalent to one tablet weight of Ramelteon were accurately 
weighed, transferred to a 100 ml volumetric flask containing 50 ml 
water and were allowed to stand to ensure complete solubility of the 
drug. The mixture was made up to volume with water. The solution 
was suitably diluted and the absorption was determined by UV–
Visible spectrophotometer. The drug concentration was calculated 
from the calibration curve. 
In vitro drug release studies 
Drug release studies of ramelteon core tablets 
The core tablets containing 8 mg Ramelteon of were tested in (pH 
6.8), for their dissolution rates. Dissolution studies were performed 
using USP paddle-type sample of 5 ml was withdrawn and replaced 
with equal volume of fresh medium. The samples were analyzed 
spectrophotometrically at respective 256 nm [12, 13]. 
Drug release studies of compression coated ramelteon tablets 
The release of ramelteon from coated tablets was carried out using 
USP paddle-type dissolution apparatus at a rotation speed of 50 
rpm, and a temperature of 37±0.5 °C. For tablets, simulation of 
gastrointestinal transit conditions was achieved by using different 
dissolution media. Thus, drug release studies were conducted in 
simulated gastric fluid (SGF, pH 1.2) for the first 2 h as the average 
gastric emptying time is about 2 h. Then, the dissolution medium 
was replaced with enzyme-free simulated intestinal fluid (SIF, pH 
7.4) and tested for drug release for 3 h, as the average small 
intestinal transit time is about 3 h, and finally, enzyme-free 
simulated intestinal fluid (SIF, pH 6.8) was used up to 18 h to mimic 
colonic pH conditions. 
Drug release was measured from compression coated Ramelteon 
tablets, added to 900 ml of dissolution medium. 5 ml of sample was 
withdrawn every time and replaced with the fresh medium; samples 
were withdrawn at various time intervals were analyzed 
spectrophotometrically at 254 nm, 256 nm and 257 nm, 
respectively. All dissolution runs were performed for six batches. 
The results were given with deviation [14, 15]. 
Kinetics of in vitro drug release 
In vitro release data is applied to all the formulations (F1-F12) as per the 
given table 3 by using the equation and find the release mechanism.
 
Table 3: Kinetics of drug release 
Type Equation Parameter 
Zero order Qt = Q0+K0 Cumulative percentage drug release vs. Time in hours  t 
First order Qt =Q0e Log cumulative percentage remained vs. Time in hours -Kt 
Higuchi Q=Kh t Cumulative percentage drug release vs. Square root of time 1/2 
Korsmeyer peppas F = (Qt/Q) = Km t Log cumulative percentage of drug release vs. Log time n 
Qt= Cumulative amount of drug release at time “t”. Q0=Initial amount of drug release, Q=Total amount of drug release in dosage forms, N= Diffusion 
of release exponent, T= Time in hours, K0, K, Kh, Km
 
 are release rate constants of Zero, First, Higuchi, Korsmeyer peppas 
RESULTS AND DISCUSSION 
Determination of absorption maxima 
A solution of containing the concentration 10 µg/ml was prepared in 
0.1N HCl, 7.4 pH and phosphate buffer 6.8pH respectively, UV 
spectrum was taken using a Double beam UV/VIS 
Parimala et al. 
Int J App Pharm, Vol 13, Issue 2, 2021, 249-253 
251 
spectrophotometer. The solution was scanned in the range of 200–
400. 
Preparation calibration curve 
10 mg of drug was accurately weighed and dissolved in 10 ml of 
0.1N HCl, 7.4 PH, and 6.8 PH in 10 ml volumetric flask, to make 
(1000 µg/ml) standard stock solution (1). Then 1 ml stock solution 
(1) was taken in another 10 ml volumetric flask to make (100 
µg/ml) standard stock solution (2), then again 1 ml of stock solution 
(2) was taken in another 10 ml volumetric flask and then final 
concentrations were prepared 2, 4,6, 8, 10, with 0.1N HCl, 0.5, 1, 1.5 
and 2 7.4 pH, and 1,2,3,4 and 5 with 6.8 pH. The absorbance of 
standard solution was determined using UV/VIS spectrophotometer 
at 254 nm, 256 nm and 257 nm. Linearity of the standard curve was 
assessed from the square of correlation coefficient (r2), which was 
determined by least-squares linear regression analysis. The graph 
plotted concentration vs. Absorbance [16, 17]. 
Fourier transforms infrared spectroscopy 
Preformulation studies 
Preformulation studies can be defined as investigations of physical and 
chemical properties of a new drug substance; either of the pure 
substance or of its combinations with other excipients. It is a phase of the 
research and development process that is required to develop stable, 
safe and effective dosage forms. These are also used for the 
determination of suitable excipients for the formulation of dosage forms. 
Drug-excipient compatibility study 
Drug excipient compatibility studies carried out by FTIR 
spectroscopy. The FTIR of pure drug and physical mixture of 
drug and excipient were studied. From FTIR, there was no 
significant change in the peaks of pure drug and excipient 
mixture [18]. Therefore it can be inferred that there was no 
specific interaction observed between the drug and the 
excipient, as shown in fig. 2 
Physical characterization of coated tablets 
All the formulations were prepared according to the formula given 
in table 1. The prepared tablets were evaluated for various physical 
properties as indicated in table 4. The results of evaluation studies 
can be summarized as follows:  
The thickness of the formulations was found to be in the range of 
4.40±0.5 mm to 4.9±0.5 mm. the crushing strength of tablets is 
found to be 4.1 to 4.5 kg/cm2. The loss in total weight of the tablets 
that is friability is less than 1%. Weight variation was found to be in 
the range of 1.18 to 1.65%. this shows that all the parameters are 
within limits and having good compressibility. Drug content is found 




Fig. 1: FTIR spectrum of pure drug 
 
 
Fig. 2: FTIR spectrum of optimized formulation 
 
Table 4: In vitro quality control parameters for compression coated tablets 
Formulation codes Weight* variation (mg) Hardness* (kg/cm2) Friability* (%loss) Thickness (mm) Drug content* (%) 
F1 303.1±2.03 4.5±0.26 0.51±0.11 4.8 99.77±0.58 
F2 304.2±3.04 4.2±0.19 0.53±0.19 4.9 99.47±0.61 
F3 299.1±2.98 4.4±023 0.52±0.15 4.9 99.35±0.78 
F4 309.3±3.47 4.5±0.17 0.56±0.17 4.9 99.89±0.45 
F5 310.3±2.87 4.4±0.24 0.57±0.16 4.7 99.15±0.54 
F6 311.5±1.99 4.2±0.31 0.46±0.11 4.5 98.57±0.49 
F7 303.4±3.75 4.1±0.17 0.53±0.19 4.4 98.45±0.48 
F8 304.6±4.12 4.3±0.19 0.48±0.18 4.7 99.66±0.51 
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F9 299.4±3.75 4.5±0.21 0.56±0.19 4.6 99.15±0.61 
*mean±SD(n=3) 
In vitro drug release of tablets 
Table 5: In vitro drug release profile for coated formulations (F1-F9) 
Time (h) F1* F2* F3* F4* F5* F6* F7* F8* F9* 
0.5 4.76±0.65 5.98±0.50 6.89±0.15 7.58±0.15 3.89±0.36 4.98±0.10 6.85±0.44 7.65±0.57 4.25±0.55 
1 10.55±0.51 11.55±0.32 15.66±0.31 16.98±0.78 12.55±0.26 12.55±0.56 14.82±0.38 10.76±0.55 8.95±0.67 
2 10.47±0.21 17.48±0.15 22.69±0.15 25.23±1.32 19.77±0.32 22.57±0.61 21.03±0.61 18.19±0.66 14.3±0.50 
3 30.68±0.32 25.44±0.56 35.63±0.50 33.64±0.55 26.76±0.21 30.86±0.46 28.6±0.84 20.98±0.56 19.88±0.60 
4 43.75±0.61 36.55±0.61 48.87±0.59 34.39±0.79 32.85±0.66 36.28±1.21 33.35±0.72 23.65±0.90 24.89±0.82 
5 49.79±0.82 38.62±0.76 52.45±0.56 45.85±0.67 38.75±0.76 38.12±0.55 45.26±0.38 27.05±0.59 28.18±0.55 
6 50.06±0.93 42.29±0.61 54.98±0.31 46.54±0.70 43.38±0.45 45.99±0.21 46.27±0.85 36.48±0.35 35.67±0.59 
7 55.65±0.15 46.72±0.55 57.72±1.11 56.77±0.61 45.23±0.70 48.37±0.71 54.25±0.72 42.68±0.70 45.35±0.75 
8 58.39±0.40 53.57±1.05 59.93±0.61 59.48±0.40 50.55±0.66 55.85±0.55 60.93±0.46 49.19±0.44 48.93±0.90 
9 67.98±0.67 58.85±0.68 65.53±1.80 62.75±0.55 57.28±0.75 57.93±0.90 65.33±0.93 55.82±0.21 52.08±0.90 
10 68.79±0.81 65.45±0.67 67.56±0.72 65.18±0.86 63.49±0.95 59.35±0.81 66.09±0.71 59.89±0.80 58.15±0.78 
11 70.35±0.52 70.89±1.00 72.83±0.44 70.57±0.72 67.76±0.68 69.78±0.84 69.37±0.70 65.55±0.40 63.65±0.82 
12 73.36±0.85 72.35±0.78 75.48±0.78 74.38±0.26 79.66±0.65 73.75±0.75 70.45±0.66 69.45±0.60 65.09±0.57 
13 77.57±0.78 76.36±0.61 77.15±0.55 79.97±0.55 83.76±0.59 76.45±0.57 73.26±0.93 72.85±0.92 69.71±0.75 
14 81.64±0.44 82.69±0.70 82.36±0.87 85.28±0.68 85.18±0.26 78.57±0.38 77.25±0.62 78.98±0.57 73.38±0.95 
15 84.55±0.47 85.93±0.61 84.78±0.78 90.96±0.31 88.67±0.56 82.18±1.81 80.8±0.55 84.53±0.66 76.45±0.75 
16 86.69±0.32 86.32±0.78 87.99±0.55 93.55±0.32 90.32±1.05 85.36±1.39 85.36±0.87 85.75±0.66 80.27±0.60 
17 88.89±0.61 89.87±0.70 89.43±1.25 95.18±1.25 91.86±0.40 87.13±0.68 87.85±0.32 88.74±0.55 82.89±0.81 
18 90.16±0.92 90.98±1.06 93.19±0.56 99.25±0.66 90.98±0.66 90.18±0.76 89.26±0.74 89.05±0.46 85.99±0.95 
*mean±SD(n=3) 
 
Table 6: Release kinetics data of ramelteon 
Formulation  Zero Order (R2) First Order (R2) Higuchi (R2) Korsmeyer-Peppas  
(R2) n 
F1 0.917 0.988 0.975 16.117 0.6127 
F2 0.975 0.974 0.981 12.48 0.703 
F3 0.925 0.971 0.988 19.72 0.54 
F4 0.978 0.851 0.986 15.37 0.645 
F5 0.973 0.956 0.97 11.744 0.735 
F6 0.969 0.978 0.987 14.11 0.649 
F7 0.950 0.982 0.989 15.91 0.605 
F8 0.987 0.96 0.956 8.86 0.818 
F9 0.984 0.981 0.987 9.05 0.789 
 
Kinetics of drug release 
Kinetics of in vitro drug release 
In vitro release data obtained is applied to all the formulations (F1-
F9) as per the table 2. The kinetic profiles of all formulations were 
shown in table 6. The correlation coefficient (r) values in the 
analysis of release data as per various models are given table 6. 
Analysis of the release data as per zero order and first-order kinetic 
models indicated that the drug release from matrix tablets followed 
first-order kinetics. All the formulations followed first order kinetics. 
This implies that the drug release is dependent on one of the 
concentrations. The correlation coefficient (r) values were higher in 
first order model when compared to zero-order models. The r-
values were also higher in the Higuchi and Peppas equation models 
indicating that the drug release from the ramelteon tablets also 
obeyed these two models. When the release date are analyzed as per 
Peppas equation, the release exponent ‘n’ is an empirical parameter 
characterizing the release mechanism [19, 20]. Mechanism of drug 
release may be determined based on the values of the diffusion 
exponent, if the value of n is 0.5 it indicates that the drug release 
mechanism is explained by a Fickian diffusion-controlled release, 
whereas if n equal to 1.0, it indicates that the drug release 
mechanism approaches to zero order release. If n value is from 0.5 
to 1, it implies that the release mechanism is non-Fickian diffusion 
or chain relaxation control release. The n value of the formulations 
was in the range of 0.540 to 0.818.  
Hence, it was concluded that the prepared formulations followed 
non-Fickian diffusion. The drug release from all the batches followed 
by non-ficikian diffusion mechanism as Higuchi’s fit shows high 
correlation coefficient values [21]. Among all the formulations F4 
formulation was found to be optimized as it was retarded the drug 
release up to 18 h and showed maximum of 99.25% drug release.  
CONCLUSION 
In the present research work formulation of ramelteon targeted to 
colon was prepared by using various polymers. Colon-targeted 
tablets were prepared in two steps. Initially, core tablets were 
prepared and then the tablets were coated by using different pH 
dependent polymers. Ethylcellulose, Eudragit L100 and Eudragit 
RLPO were used as enteric coating polymers. The pre-compression 
blend of all formulations was subjected to various flow property 
tests and all the formulations were passed the tests. The tablets 
were coated by using polymers and the coated tablets were 
subjected to various evaluation techniques. The tablets were passed 
all the tests. Among all the formulations, F4 formulation was found 
to be optimized as it was retarded the drug release up to 18 h and 
showed maximum of 99.25% drug release. It followed the first order 
kinetics mechanism. 
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